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In 2015, several provinces in Lao People’s Democratic Republic (Lao PDR) experienced a
vaccine-derived poliovirus outbreak. This survey was conducted (i) to evaluate the vaccina-
tion coverage in different settings and cohorts using the seroprevalence of anti-poliovirus
(PV) antibodies as a surrogate measure, and (ii) to explore the usefulness of an ELISA in a
country with limited resources and a specific epidemiological setting. IgG antibodies were
assessed by ELISA in Lao children (n = 1216) and adults (n = 1228), including blood donors
and health care workers. Protective antibody titers against the 3 vaccine serotypes were
determined by microneutralization (VNT) in a subset of participants. More than 92% of the
children had anti-poliovirus antibodies, regardless of nutritional status or access to health
care, highlighting the success of the vaccination outreach activities in the country. In con-
trast, anti-poliovirus seroprevalence reached only 81.7% in blood donors and 71.9% in
health care workers. Participants born before the introduction of poliovirus vaccination in
Lao PDR were considerably less likely to be seropositive. These findings align with the epi-
demiology of the outbreak. Neutralizing antibodies against at least one of the 3 poliovirus
serotypes were detected in all children (99/99) and 93/99 had antibodies against all sero-
types. Similarly, all health care workers had neutralizing antibodies against at least one and
92/99 against all serotypes. The comparison of both assays shows an acceptable underesti-
mation of vaccine coverage in children by ELISA, but a low sensitivity of the ELISA in the
adults. We show that the ELISA is a reasonable alternative to the VNT in particular in vacci-
nated children, that an improved version should be serotype specific, and that negativity
thresholds should be revisited for optimal sensitivity and specificity. Thus, polio-free coun-
tries with an uncertain vaccination coverage and limited laboratory capacity, that are at risk
of vaccine-derived poliovirus outbreaks or of re-importation of wild poliovirus may benefit
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Introduction
Large-scale vaccination campaigns eliminated wild poliovirus (WPV) in most countries of the
world and WPV remains endemic only in Pakistan, Nigeria and Afghanistan [1]. In the Lao
People’s Democratic Republic (Lao PDR), oral polio vaccine (OPV) was introduced in the
early eighties, and vaccination was expanded to the whole country in the nineties [2]. In 1996,
the last case of WPV was reported in Lao PDR and in 2000, the Western Pacific Region,
including Lao PDR, was certified polio-free [3, 4].
Despite its ground-breaking role in the eradication of poliovirus (PV), OPV (containing
live attenuated PV strains) has some important drawbacks. A small proportion of vaccinees
develop vaccine-associated paralytic poliomyelitis (VAPP, reviewed in [5]). In countries with
suboptimal vaccination coverage levels and weak acute flaccid paralysis (AFP) surveillance,
excreted vaccine-virus can replicate and circulate for a prolonged time. Within less than a year
of circulation, vaccine viruses may accumulate genetic mutations and neurovirulent vaccine-
derived PV (VDPV) may emerge [6].
At the end of 2015, VDPV type 1 strains emerged in Lao PDR and caused paralysis in 11
individuals (last case in January 2016) in the three neighbouring provinces Bolikhamxay, Xai-
somboun and Vientiane Province (see also Fig 1). Most of the affected patients were male; 4
were below the age of 18 months, 4 between 4 and 15 years, and 2 were in their forties. Only a
one-year old child had completed the three OPV vaccinations. The others had only one or no
dose of OPV. Virtually all belonged to the ethnic group of the Hmong. Circulation of the
VDPV (cVDPV) was confirmed by epidemiological investigations and molecular analyses. By
the beginning of 2016, the outbreak was declared a public health emergency by the Prime Min-
ister and large vaccination campaigns with trivalent OPV were launched and surveillance was
intensified throughout the country [7, 8].
To reduce the risk of cVDPV emergence and in compliance with the Polio End Game Strat-
egy [9], a switch from trivalent (containing type 1, 2 and 3 vaccine strains) to bivalent (contain-
ing type 1 and 3 vaccine strains) OPV was globally implemented in 2016 [9–11]. In Lao PDR,
the new recommendations, introduction of bivalent OPV and of Inactivated polio vaccine
(IPV) as an adjunct to routine immunization with OPV will soon be implemented.
Currently, PV surveillance relies mainly on the reporting of AFP and in Lao PDR, reported
rates of AFP reached almost the recommended minimum required for PV-free countries (i.e.
one per 100 000 children below 15 years of age) [12]. However, PV surveillance remains chal-
lenging as silent circulation of WPV and VDPV is frequent. The microneutralization assay
(VNT) is well recognized as the gold standard for measuring neutralizing antibodies against
PV and as a correlate of protection [13]. Therefore, it is also the best assay for assessing popula-
tion immunity. However, the assay is time- and resource-consuming, and major restrictions
apply to its use. Thus the capacity to perform population or cohort studies with this assay is
limited even in fully accredited polio laboratories. Only recently, storage and handling of type
2 PV has been prohibited even in most polio reference laboratories. In the future, working
with live PV will be subject to further restrictions in particular when poliomyelitis will be erad-
icated. Also, not all sera collected under difficult field conditions may be suitable for VNT (e.g.
sterility, quantities). Moreover, countries and courier services become increasingly reluctant to
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ship specimen to specialized laboratories and costs are often prohibitive. With the global intro-
duction of injectable IPV into national immunization programs, the relative importance of
serum IgG detection will likely increase. In contrast to the VNT, an ELISA can be performed
with little limitations in most laboratories. Therefore it could be a simple and valuable alterna-
tive to the very limiting VNT, complementing the VNT in the polio endgame.
Not enough is known in Lao PDR about immunity levels against PV to understand the rea-
sons for the recent VDPV outbreak. We investigated five large cohorts with different demo-
graphic, exposure and vaccination histories. As Lao PDR has no laboratory to perform VNT,
this assay was done at the Robert Koch Institute in Berlin. Our study explored the usefulness
of a commercial polio IgG ELISA as a surrogate measure of vaccination coverage and provides
important public health information about polio epidemiology.
Fig 1. Lao provinces. Provinces affected by the cVDPV type 1 outbreak are represented in grey and provinces
included in the study are marked with crosses. Reprinted from Political map of Laos under a CC BY license, with
permission from [www.onestopmap.com], original copyright 2015.
https://doi.org/10.1371/journal.pone.0197370.g001
Poliovirus immunity in Lao People’s Democratic Republic
PLOS ONE | https://doi.org/10.1371/journal.pone.0197370 May 15, 2018 3 / 13
Material and methods
Participants
Serum samples from 5 different cohorts, collected before the 2015 cVDPV outbreak for sero-
prevalence studies on infectious diseases, were included. We selected our cohorts from urban
or rural areas of the provinces affected by the recent VDPV type 1 outbreak (Bolikhamxay,
Vientiane Capital and Xaisomboun) or provinces neighboring the latter. Both, children and
adults, with known and unknown vaccination status, as well as health care workers (HCW) as
a risk group in the case of an outbreak were included. Although all cases occurred in an ethnic
minority from remote areas, ethnicity was for ethical reasons not captured in our study. For
each participant, birth year and sex were available. Serum and data collection were performed
anonymously after obtaining written informed consent by the participant or the participant’s
legal guardian. The studies were approved by the National Ethics Committee for Health
Research of the Ministry of Health in Lao PDR (Ethical approval reference NECHR 2013–860,
2013–732, 2014–059, 2013–038 and 2017–016).
Fully vaccinated children (Cohort 1). This cohort included 806 children, aged less than
3.5 years. All children had complete Health Center records of three doses of pentavalent vac-
cine and of OPV. Until May 2016, the 3 doses of OPV were given together with the pentavalent
vaccine at weeks 6, 10 and 14. The presence of antibodies against tetanus as determined in a
previous study [14] was used as a proxy for attending the vaccination session. In 2013 and
2014, samples were collected in 2 provinces with VDPV type 1 cases in 2015/2016 (Bolikham-
xay and Vientiane) and in an adjacent province (Khammouane) (Fig 1). The following nutri-
tional indicators were calculated: WHZ (weight-for-height Z-scores), HAZ (height-for-age Z-
scores) and WAZ (weight-for-age Z-scores). Moreover, birthplace (i.e. home or hospital) was
recorded (Table 1).
Children from remote areas (Cohort 2). In 2013, a total of 90 children aged less than 5
years were recruited in two districts (Xam Tai and Kuan) from Huaphan province. This poor
and hard-to-reach province borders on Xaysoumboun which reported VDPV type 1 cases in
the recent outbreak (Fig 1). Distance to the next health care facility (greater or less than 100
minutes by the most rapid means of transportation) was registered as proxy for access to health
care (Table 1).
Children with unknown vaccination status (Cohort 3). In 2012, 320 children aged less
than 9 years and with unknown OPV status were recruited from 3 provinces (i.e. Bolikhamxay,
Vientiane and Luang Prabang) (Fig 1).
Blood donors (Cohort 4). This cohort from 2014 included 528 blood donors, aged 16 to
56 years, and with unknown vaccination status from 4 provinces (i.e. Vientiane, Huaphan,
Khammouane and Xaiyabury) (Fig 1).
Healthcare workers (Cohort 5). This cohort included 700 HCW aged between 15 and 69
years and with different clinical and non-clinical positions. Sample collection took place in
2013, in 3 central, 2 provincial and 8 district hospitals located in Vientiane capital, Huaphan
and Bolikhamxay provinces (Fig 1).
Laboratory analysis
IgG antibodies against the three PV types were detected using a Poliovirus IgG ELISA kit
(Immuno-Biological Laboratories-America, Minnesota, USA) according to the manufacturer’s
instructions. Samples with antibody levels of 10U/mL±20% were considered borderline. This
ELISA assay detects neutralizing and non-neutralizing antibodies and is not suitable for intra-
typic (i.e. vaccine-derived or wild-type virus) and inter-typic (i.e. PV types 1–3) differentiation
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Table 1. Association between socioeconomic characteristics and anti-polio IgG seropositivity as determined by ELISA for each study cohort.
# Cohort Predictor (significance level) Categories % of Total Anti-Polio seroprevalence
n (%)a n (%)b
#1 Fully vaccinated children
(N = 806)
Total Cohort 100 787/806 (97.6) 757/776 (97.6)
Province () Bolikhamxay 26.1 199/210 (94.8) 188/199 (94.5)
Khammouane 42.9 345/346 (99.7) 338/339 (99.7)
Vientiane 31 243/250 (97.2) 231/238 (97.1)
Age group  1 year 8.9 70/72 (97.2) 69/71 (97.2)
1 year > x 2 years 52.1 408/420 (97.1) 391/403 (97)
2 years > x 3.5 years 39 309/314 (98.4) 297/302 (98.3)
Sex Female 51.4 405/414 (97.8) 389/398 (97.7)
Male 48.6 382/392 (97.5) 368/378 (97.4)
Birthplace Home 30 239/242 (98.8) 230/233 (98.7)
Hospital 70 548/564 (97.2) 527/543 (97.1)
WHZ  -2 89.1 699/718 (97.4) 672/691 (97.3)
< -2 8.1 65/65 (100) 62/62 (100)
Unknown 2.8 N/A N/A
HAZ  -2 57 448/459 (97.6) 430/441 (97.5)
< -2 39 307/315 (97.5) 297/305 (97.4)
Unknown 4 N/A N/A
WAZ  -2 78.5 616/633 (97.3) 592/609 (97.2)
< -2 20.8 166/168 (98.8) 160/162 (98.8)
Unknown 0.7 N/A N/A
#2 Children from remote areas
(N = 90)
Total Cohort 100 88/90 (97.8) 84/85 (98.8)
District Xam Tai 58.9 51/53 (96.2) 49/50 (98)
Kuan 41.1 37/37 (100) 35/35 (100)
Age group <2 years 16.7 15/15 (100) 15/15 (100)
2 years x > 3years 22.2 19/20 (95) 18/19 (94.7)
3 years x 5 years 61.1 54/55 (98.2) 51/51 (100)
Sex Female 43.3 39/39 (100) 36/36 (100)
Male 56.7 49/51 (96.1) 48/49 (98)
#3 Children with unknown vaccination status
(N = 320)
Total Cohort 100 297/320 (92.8) 277/300 (92.3)
Province () Bolikhamxay 30.6 84/98 (85.7) 74/88 (84.1)
Luang Prabang 43.8 134/140 (95.7) 124/130 (95.4)
Vientiane 25.6 79/82 (96.3) 79/82 (96.3)
Age group ()  1 year 39.1 122/125 (97.6) 122/125 (97.6)
5 years x 9 years 60.9 175/195 (89.7) 155/175 (88.6)
Sex Female 51.3 152/164 (92.7) 146/158 (92.4)
Male 48.7 145/156 (93) 131/142 (92.3)
#4 Blood donors (N = 528) Total Cohort 100 441/528 (83.5) 389/476 (81.7)
Province Huaphan 15.3 67/81 (82.7) 60/74 (81.1)
Khammouane 48.7 215/257 (83.7) 185/227 (81.5)
Vientiane 25.8 113/136 (83.1) 104/127 (81.9)
Xaiyabury 10.2 46/54 (85.2) 40/48 (83.3)
Birthyear group () 1989–1998 50.4 230/266 (86.5) 206/242 (85.1)
1978–1988 32.4 144/171 (84.2) 129/156 (82.7)
1958–1977 17.2 67/91 (73.6) 54/78 (69.2)
Sex Female 38.8 175/205 (85.4) 162/192 (84.4)
Male 61.2 266/323 (82.4) 227/284 (80)
(Continued)
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of poliovirus antibodies. Neutralizing antibodies against the 3 vaccine strains (Sabin 1–3) were
determined by VNT at the Polio Reference Laboratory at the Robert Koch Institute in Berlin,
following the WHO protocol [13]. Only partial antibody titration was performed and the anti-
body titer cutoff for protection was 8. The VNT was performed only on a subset of the samples
(n = 198; 99 of Cohort 1 and 99 of Cohort 5) since the Robert Koch Institute did not have the
capacity to test all cohorts and specimens for study purposes. While restrictions applied for
performing VNT in our fully equipped BSL2/BSL3 laboratory, there were no such limitations
for performing ELISAs.
Statistical analyses
Statistical analyses were performed in R software (version 3.3.1.; R Foundation for Statistical
Computing, Vienna, Austria) [http://www.R-project.org] using the packages ‘MASS’ [15],
‘fmsb’[http://CRAN.R-project.org/package=fmsb], ‘epitools’ [http://CRAN.R-project.org/
package=epitools], ‘aod’ [http://cran.r-project.org/package=aod], ‘ggplot2’[16], ‘car’ [17],
‘cowplot’ [https://CRAN.R-project.org/package=cowplot] and ‘Rcpp’ [18]. We observed little
difference in results whether borderline samples (10U/ml±20%) were considered positive or
were ignored (Table 1). Our statistical analysis was based on a dataset without borderline sam-
ples. Univariate, bivariate and multivariate analyses were conducted to assess factors associated
with immunization status (i.e. seropositive or seronegative). We used two-tailed Fisher’s exact
test or Yates’s corrected χ2 test, as appropriate, to compare categorical variables and t-test to
compare quantitative variables. Binary logistic regression was applied to estimate the probability
of PV seropositivity given the values of following explanatory variables: age, birth year, sex,
birthplace, or province. Pearson correlation coefficient was calculated to measure the associa-
tion between anti-PV antibody levels and age, and between anti-PV antibody levels determined
by ELISA and neutralizing antibody titers determined by VNT. A p-value less than 0.05 was
considered statistically significant and a p-value less than 0.01 was considered highly significant.
Table 1. (Continued)
# Cohort Predictor (significance level) Categories % of Total Anti-Polio seroprevalence
n (%)a n (%)b
#5 Healthcare workers (N = 700) Total Cohort 100 536/700 (76.6) 420/584 (71.9)
Location hospital Central or provincial 72.7 388/509 (76.2) 304/425 (71.5)
District 27.3 148/191 (77.5) 116/159 (73)
Birthyear group 1989–1998 12.4 72/87 (82.8) 59/74 (79.7)
1978–1988 29.3 160/205 (78.1) 130/175 (74.3)
1958–1977 58.3 304/408 (74.5) 231/335 (69)
Sex Female 78.7 429/551 (77.9) 335/457 (73.3)
Male 21.3 107/149 (71.8) 85/127 (66.9)
Position Lab technician 7.3 41/51 (80.4) 35/45 (77.8)
General physician 21 112/147 (76.2) 90/125 (72)
Nurse 53.9 287/377 (76.1) 219/309 (70.9)
Others 12.1 64/85 (75.3) 51/72 (70.8)
Specialist physician 5.7 32/40 (80) 25/33 (75.8)
aComplete dataset, borderlines being considered positive
bDataset without borderline samples
significant effect on anti-poliovirus antibody seroprevalence (p-value between 0.05 and 0.01)
highly significant effect on anti-poliovirus antibody seroprevalence (p<0.01)
https://doi.org/10.1371/journal.pone.0197370.t001
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Results
Seroprevalence in children (Cohorts 1–3)
97.6% of the children with full vaccination records and aged less than 3.5 years had IgG anti-
bodies against PV by ELISA (Cohort 1). Neither sex or age, nor birthplace or nutritional status
influenced PV immune status. However, seropositivity rates differed significantly between the
3 provinces (χ2 = 14.7, df = 2, p<0.01; Table 1).
An anti-PV antibody seroprevalence of 98.8% was determined by ELISA in children aged
less than 5 years from remote districts in Huaphan (Cohort 2). Neither age or sex, nor distance
to next health care facility had a significant effect on PV immune status (Table 1). In another
cohort of children with unknown vaccination status from less marginalized communities
(Cohort 3), antibody seroprevalence was somewhat lower with 92.3%. Similarly to what was
found for cohort 1, significantly lower immunity rates were also found for this cohort in Boli-
khamxay (84.1%) than in the two other provinces (Luang Prabang: 95.4%, OR = 3.9, 95%
CI = 1.4–10.6, p = 0.01; Vientiane: 96.3%, OR = 4.9, 95%CI = 1.4–18, p = 0.007). Children aged
less than 1 year were significantly more likely to have anti-PV antibodies than children aged 5
to 9 years (97.6% versus 88.6%, p = 0.007) and anti-PV antibody levels were negatively corre-
lated with age (Pearson’s r = -0.4; 95%CI = -0.5 and -0.3; t = -7.1, df = 318, p<0.001).
Seroprevalence in adults (Cohorts 4 and 5)
81.7% of the blood donors (Cohort 4) had antibodies against PV by ELISA. Seroprevalence
rates ranged from 81.1 to 83.3% in the 4 provinces with no significant differences. Participants
born after the introduction of OPV into the national immunization program in 1979 were sig-
nificantly more likely to be seropositive: only 69.2% of the birth cohort 1958–1977 were sero-
positive, compared to 82.7 and 85.1% of the younger birth cohorts (1978–1988: OR = 2.1, 95%
CI = 1.1–4, p = 0.028; 1989–1998: OR = 2.5, 95%CI = 1.4–4.6, p = 0.003) (Table 1, Fig 2A).
Anti-PV antibody levels correlated negatively with age (Pearson’s r = -0.1; 95%CI = -0.2 and 0;
t = -3.6, df = 526, p = 0.001) (Table 1, Fig 2B). Mean antibody levels were significantly lower in
blood donors (47.6, 95%CI = 18.2–69.6) than in the fully vaccinated children (79.1; 95%
CI = 47.7–79.1) (t = -14.3, df = 1031.5, p-value<0.001; Fig 2C).
Overall, a lower seroprevalence was determined for HCW (Cohort 5) than for blood
donors: only 71.9% of the HCW had antibodies against PV by ELISA. Also in this adult cohort,
the antibody seroprevalence decreased with age from 79.7% (birth year 1989–1998), to 74.3%
(birth year 1978–1988), to 69% (birth year 1958–1977), but between the youngest and the
oldest cohort there was only a trend to significance (p = 0.067). Anti-PV antibody levels were
negatively correlated with age (Pearson’s r = -0.2; 95%CI = -0.2 and -0.1; t = -2.9, df = 698,
p-value = 0.004). The other recorded risk factors wee rnot significant (Table 1).
Performance characteristics of the ELISA compared to the VNT assay
Subsets of Cohort 1 (n = 99) and Cohort 5 (n = 99) were tested by both, VNT and ELISA. Regres-
sion analysis showed no significant correlation between the antibody titers determined by VNT
and the antibody levels (in arbitrary units) determined by ELISA. While 80.8% of the fully vacci-
nated children of this Cohort 1 subset were positive for anti-polio IgG antibodies by ELISA, essen-
tially all had protective antibodies against PV types 1 and 2 (99%) and against PV type 3 (94.9%)
by VNT. 93.9% of the children had protective antibodies even against all three PV types (Table 2).
In the HCW subset (Cohort 5), 49.5% were positive for anti-polio IgG antibodies by ELISA, but
essentially all had protective antibodies to PV type 2 (99%) and PV types 1 and 3 (97%) by VNT.
92.9% of the HCW had protective antibodies to all three PV types (Table 2).
Poliovirus immunity in Lao People’s Democratic Republic
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Fig 2. Age-related differences in poliovirus immunity as determined by ELISA. (A) Differences in age between
seronegative and seropositive blood donors and (B) age-stratified anti- poliovirus antibody levels in blood donors. The
regression line and the confidence interval (shaded) are shown. (C) Differences in median antibody levels between
fully vaccinated children (Cohort 1) and blood donors (Cohort 4).
https://doi.org/10.1371/journal.pone.0197370.g002
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Since every child and HCW had neutralizing antibodies against at least one PV type, the
ELISA underestimated the “vaccination coverage” lacking some sensitivity: At the cut-off pro-
posed by the manufacturer (10U/mL±20%), the sensitivity for Cohort 1 was technically 80.8%
while the sensitivity to predict antibodies against any particular PV type or against all 3 PV types
was 80.6 to 83% (Table 2). The corresponding sensitivities for Cohort 5 ranged between 48.9 to
50% (Table 2). If the cut-off was lowered to the lower limit of the grey-zone (8 U/ml) the sensitivi-
ties increase from 97.6% and 76.6% to about 98.1% and 80.6% for both cohorts respectively (Fig
3). At a cut-off of 7U/ml, i.e. slightly below the grey-zone the sensitivity of the ELISA would reach
>99% in the child cohort 1 and an acceptable 88.1% in the adult Cohort 5. Assuming that also all
participants of Cohort 2, 3, and 4 are positive for at least one PV serotype, the sensitivities for
these cohorts would increase from 97.8%, 92.8% and 83.5% to 98.9%, 94.4%, and 88.8%, respec-
tively. However, the specificity and the effect of lowering the positivity threshold on specificity
could not be evaluated since there were no VNT-negatives for all 3 PV types available.
Discussion
To reduce the risk of WPV re-importation in Lao PDR [19, 20], the immunization services
were strengthened nationwide [21]. In 2015, the OPV vaccination coverage was estimated at
Table 2. Sensitivity of the ELISA against the microneutralization assay.
Neutralizing antibodies against the 3 PV types (by VNT)
PV type 1 PV type 2 PV type 3 PV type 1–3
n (%) n (%) n (%) n (%)
#1 Fully vaccinated children (N = 99) Total cohort 98 (99.0) 98 (99.0) 94 (94.9) 93 (93.9)
Anti-PV IgG antibodies (80.8% seropositivity by ELISA) 80 (81.6) 79 (80.6) 78 (83.0) 77 (82.8)
#5 Healthcare workers (N = 99) Total cohort 96 (97.0) 98 (99.0) 96 (97.0) 92 (92.9)
Anti-PV IgG antibodies (49.5% seropositivity by ELISA) 48 (49.0) 49 (50.0) 47 (50.0) 46 (49.5)
https://doi.org/10.1371/journal.pone.0197370.t002
Fig 3. Technical sensitivity of the ELISA relative to a moving cut-off for seropositivity. The dashed lines represent the sensitivity of the subset
of samples tested by VNT of both Cohorts 1 and 5 (Fully vaccinated children and Healthcare workers). The solid line corresponds to the sensitivity
of the complete Cohorts 1–5.
https://doi.org/10.1371/journal.pone.0197370.g003
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89% for 12–23 months old children [22]. Nevertheless, in the same year, the country experi-
enced a cVDPV type 1 outbreak.
We find here that overall well above 90% of children had antibodies against PV. This was
true even for a rural cohort of children with unknown vaccination status (Cohort 2). This high
seroprevalence is also largely due to a very high vaccine efficacy: 97.6% of fully vaccinated chil-
dren (Cohort 1) were positive for anti-PV antibodies by ELISA. Although weak vaccine
responses to OPV have been reported in chronically malnourished children [23], we observed
no effect of malnutrition on antibody levels. Also no significant difference in PV immunity
was found between children born at home and children born in hospital settings. Remarkably,
the cohort of children from remote districts in Huaphan were equally well protected as the
fully vaccinated children, and distance to the next health care facility had no negative impact
on their immune status. This suggests a high efficiency of outreach vaccination activities. How-
ever, significantly lower seropositivity rates were determined in Bolikhamxay, both for fully
vaccinated children (94.5%) and children with unknown OPV status (84.1%). This is also the
province which notified the first paralytic cases during the outbreak. Deficiencies related to
vaccine management may also have influenced OPV efficacy [24–26].
In our adult cohorts, we found that only 81.7% of the Lao blood donors and 71.9% of the
HCW had anti-PV antibodies by ELISA. There was no significant difference between blood
donors from different provinces and between HCW from central, provincial or district hospi-
tals or with different clinical and non-clinical positions. In both adult cohorts, older partici-
pants and particularly those born before the introduction of OPV in the country had
significantly lower anti-PV antibody levels and, were significantly less likely to be seropositive
(Fig 2A and 2B) than younger adults or the children of Cohort 1 and 2. Adults born before the
eighties did not undergo routine vaccination and were also less likely to participate in SIAs.
The significant age-dependent decrease in total anti-PV antibodies determined by ELISA
among all adult cohorts could thus be a reflection of the lower vaccination coverage in this age
group, or of the waning immunity after vaccination or exposure to VDPV or WPV. This may
also explain why four of the eleven reported paralytic cases occurred among individuals above
the age of 14 years.
As mentioned before, the gold-standard for testing immunity is the VNT. Because of its
restricted use, we could test only selected subsets of samples from two cohorts: The cohort of
children (Cohort 1) with documented recent vaccination was assumed to be most likely to
have antibodies against PV, allowing to test the sensitivity of the assays against vaccination rec-
ords. Conversely, this cohort also served to measure the seroconversion i.e. efficacy of recent
vaccination activities. The cohort of health care workers (Cohort 5) was selected as an example
of an adult population. In addition, it represents a group with a particular risk in the case of an
outbreak. Whereas Cohort 1 was largely ELISA positive, the latter cohort had a sizable propor-
tion of ELISA negatives, allowing to test also negatives by VNT. The ELISA serologies of the
other children’s cohorts (Cohort 2, 3) and the other adult cohort (Cohort 4) matched the
results of Cohort 1 and cohort 5, respectively. Thus, Cohorts 1 and 5 were adequate choices for
being tested by VNT.
The VNT results were similar in both subsets with all cohort members having antibodies at
least against one PV type, demonstrating that both the vaccination coverage and the vaccine
response are highly satisfactory. Nevertheless, only 49.5% of the adult subset and 80.8% of the
child subset were positive by ELISA. This shows a significant lack of sensitivity of the ELISA
compared to the VNT in both cohorts. The sensitivity of the ELISA could be improved by low-
ering the threshold for positivity below the recommended threshold, albeit normally at the
expense of more false positives, i.e. a reduced specificity. Because all specimens tested by VNT
had antibodies against at least one PV type, it was not possible to estimate the specificity of this
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trivalent ELISA against the monovalent VNTs in the Lao setting. Interestingly, the vast major-
ity of vaccinated children (93.9%) and of the adults with unknown vaccination status (92.9%)
tested by VNT had protective antibodies against the 3 PV types. Thus, overall, 87.1–91.8% of
the children and 71.2–77.6% of the adult cohort would have antibodies against the three PV
types.
The discrepancy between the two assays, particularly conspicuous in the adults born before
(37.9%) and after (58%) the introduction of OPV in the early eighties may be explained by the
lower vaccination coverage rates or waning of antibodies after WPV or VDPV exposure.
While neutralization is a reliable correlate of protection [24], Lao adults born before OPV
introduction may be sufficiently protected against disease, but not necessarily against infection
[25]. Silent spreading of PV [26, 27] may favor the re-emergence of cVDPV in particular in
high-risk areas. While an overestimation would not be tolerable, the ELISA used provided an
acceptable underestimation of the vaccine coverage in children. Thus, countries with an uncer-
tain vaccination coverage and/or vaccine response, that are at risk of VDPV or re-importation
of WPV and/or plan to switch from OPV to IPV and that cannot perform VNT, may benefit
from an improved version of such an ELISA for cohort studies to evaluate their immunization
programme in children. Our results show that in settings that were declared polio-free since
time of vaccination of the cohort, antibodies can largely be attributed to the trivalent vaccina-
tion, in particular if they are directed against the three PV types, as we have shown by VNT. As
Lao PDR is polio-free since 2000, seropositivity by ELISA is highly indicative of vaccination
with trivalent OPV and not of exposure to cVDPV or WPV. Nevertheless an improved ELISA
should be serotype specific and negativity thresholds should be revisited for optimal sensitivity
and specificity. The value of measuring different isotypes and isotype subclasses including
secretory IgA should be explored [28, 29].
Conclusions
Thus, our seroprevalence results are in line with what was observed during the outbreak. How-
ever, a limitation of our cohorts was that for ethical reasons we were unable to collect explicit
information on ethnicity, while ethnic minority communities were most affected by the out-
break. These and adult risk groups such as HCWs, and regions with weak vaccination pro-
grams should be primarily targeted by future supplementary vaccination activities.
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